Authors
Latest:
Dr. Lekakis on Managing the Toxicity of CAR T-Cell TherapyLazaros John Lekakis, MD, associate professor of clinical medicine, Sylvester Comprehensive Cancer Center, University of Miami, discusses managing the toxicity of CAR T-cell therapy.
Latest:
Dr. Nimer on CAR T-Cell Therapy in Hematologic MalignanciesStephen D. Nimer, MD, professor of medicine, director, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses the use of chimeric antigen receptor (CAR) T-cell therapy in hematologic malignancies.
Latest:
Safety of Frontline Durvalumab Combo Confirmed in Extensive-Stage Small Cell Lung CancerFew immune-mediated adverse events were observed with frontline durvalumab plus platinum-based therapy and etoposide in patients with extensive-stage small cell lung cancer, and no treatment-emergent antidrug antibodies were elicited by the PD-L1 inhibitor, according to an analysis of the phase III CASPIAN trial reported at the 2019 ESMO Immuno-Oncology Congress.
Latest:
Dr. Adusumilli on the Rationale for Mesothelin-Targeted CAR T-Cell TherapyPrasad S. Adusumilli, MD, surgeon, deputy chief of Thoracic Service, co-director of the Mesothelioma Program, head of Solid Tumors Cell Therapy, Cellular Therapeutics Center, at Memorial Sloan Kettering Cancer Center, discusses the rationale for an autologous mesothelin-targeted CAR T-cell therapy in advanced solid tumors.
Latest:
Dr. Duncan on the Expansion of CAR T-Cell TherapyChristine N. Duncan, MD, a senior physician at Dana-Farber Cancer Institute, and assistant professor of pediatrics, Harvard Medical School, discusses the expansion of CAR T-cell therapy in oncology.
Latest:
Dr. Galal on Managing AEs Linked With CAR T-Cell TherapyAhmed Galal, MD, instructor, Department of Medicine, Duke Cancer Institute, discusses the management of adverse events (AEs) associated with CAR T-cell therapy.
Latest:
Dr. Banna on the Potential for CAR T-Cell Therapy in Lung CancerGiuseppe L. Banna, MD, consultant, Medical Oncology, Cannizzaro Hospital, discusses the potential for CAR T-cell therapy in the treatment of patients with lung cancer.
Latest:
Dr. Sweetenham on Unanswered Questions With CAR T-Cell Therapy in Pediatric ALLJohn Sweetenham, MD, associate director for clinical affairs, Harold G. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, discusses unanswered questions with CAR T-cell therapy in pediatric acute lymphoblastic leukemia.
Latest:
Dr. Maziarz on Unanswered Questions With CAR T-Cell Therapy in DLBCLRichard T. Maziarz, MD, professor of medicine at Oregon Health & Science University, Knight Cancer Institute, discusses unanswered questions with CAR T-cell therapy in diffuse large B-cell lymphoma.
Latest:
Mazyar Shadman, MD, on Growing Research Trends in LBCLThe associate professor at Fred Hutch Cancer Center discussed trends he observed in the field in 2023 and at ASH 2023.
Latest:
Navigating CAR T-Cell Therapy Referrals: Bijal Shah, MD; Michael Wang, MDThe hematologists from Moffitt Cancer Center and University of Texas MD Anderson Cancer Center discussed navigating the referral process for CAR T-cell therapy in hematologic malignancies.
Latest:
Dr. Sehgal on the Structure and Manufacturing Process of CAR T CellsAlison Rager Sehgal, MD, assistant professor of medicine, University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center, discusses the structure and manufacturing process of CAR T cells.
Latest:
Targeting CD19 With CAR T in R/R DL B-Cell Lymphoma: Brian T. Hill, MD, PhD; Mazyar Shadman, MD, MPHDoctors from University of Washington and Cleveland Clinic discussed targeting CD19 in CAR T-cell therapy for relapsed/refractory DLBCL.
Latest:
FasTCAR Cell Therapy Granted Orphan Drug Designation for Multiple MyelomaThe designation follows durable responses seen in a phase 1 study of the agent.
Latest:
Dr. Sehgal on the Clinical Implications of CAR T-Cell Therapy in DLBCLAlison R. Sehgal, MD, assistant professor of medicine, hematologist/medical oncologist, University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center, discusses the clinical implications of CAR T-cell therapy in diffuse large B-cell lymphoma (DLBCL).
Latest:
Dr. Hou on the Latest Updates With CAR T-Cell Therapy in DLBCLJing-Zhou Hou, MD, PhD, co-chair of the Hematological Malignancies program, and medical oncologist, hematologist, and clinical instructor at University of Pittsburgh Medical Center Hillman Cancer Center, discusses the latest updates with CAR T-cell therapy in diffuse large B-cell lymphoma (DLBCL).
Latest:
Outpatient CAR T-Cell Therapy Found Safe, Effective in Large B-Cell LymphomaCarlos R. Bachier, MD, discusses the use of CAR T-cell therapy in the outpatient setting. He also shared insight on the evolving paradigm of graft-versus-host disease.
Latest:
Dr. Mei on Investigational CAR T-Cell Therapies and Antibody-Drug Conjugates in Hodgkin LymphomaMatthew G. Mei, MD, assistant clinical professor, Department of Hematology and Hematopoietic Cell Transplantation, and hematologist/oncologist, City of Hope, discusses investigational CAR T-cell therapies and antibody-drug conjugates (ADCs) in Hodgkin lymphoma.
Latest:
Axi-cel as Frontline Therapy for High-Risk Large B-cell Lymphoma Produces Encouraging ResponsesIn 37 evaluable patients, the objective response rate in the study was 89% (95% CI, 75%-97%) with complete responses in 78%.
Latest:
Dr. Santomasso on Managing CNS Toxicity from CAR T-Cell Therapy for B-Cell LymphomaBianca D. Santomasso, MD, PhD, discusses how she prevents central nervous system toxicity due to CAR T-cell therapy for aggressive B-cell lymphoma in her own practice.
Latest:
Dr. Sotomayor on the Durability of CAR T Cells in Hematologic MalignanciesEduardo Sotomayor, MD, professor of medicine, Department of Hematology and Oncology, and director, GW Cancer Center, discusses the durability of CAR T cells, as well as ways to combat immune escape mechanisms in hematologic malignancies.
Latest:
Dr. Marasco on Engineering CAR T CellsWayne A. Marasco, MD, PhD, discusses ways CAR T cells are being engineered to avoid on-target adverse events in solid tumors.
Latest:
Dr. Shah on CAR T-Cell Therapy in Pediatric ALLNirali N. Shah, MD, MHSc, discusses the use of CAR T-cell therapy in pediatric patients with acute lymphocytic leukemia.
Latest:
CAR T-Cell Expansion Indicative of Response in B-cell LymphomaResearch presented at the EBMT meeting suggests cell expansion may be a good biomarker of both response and outcomes.
Latest:
KTE-X19 Demonstrates Comparable Pharmacologic, Clinical Outcomes to Approved Therapies in MCLThe pharmacodynamic profile of KTE-X19, an autologous anti-CD19 CAR T-cell therapy, was associated with efficacy and treatment-related neurological events among patients with relapsed/refractory mantle cell lymphoma treated within the ZUMA-2 trial.
Latest:
Early Research Signals Potential for CAR T-Cell Therapy in EGFRvIII-Positive GBMA pilot study of the efficacy of CAR T-cell therapy in patients with EGFRvIII-positive glioblastoma multiforme (GBM) has generated encouraging findings.
Latest:
Dr. Brudno on Allogeneic T Cells Expressing an Anti-CD19 CAR in B-Cell MalignanciesJennifer N. Brudno, MD, medical oncology fellow, National Cancer Institute, discusses a study examining allogeneic T cells expressing an anti-CD19 chimeric antigen receptor (CAR), which was found to cause remissions of B-cell malignancies after allogeneic hematopoietic stem cell transplantation without causing graft-versus-host disease.
Latest:
Using CAR T Therapy in R/R Multiple MyelomaNina Shah, MD, and other experts discuss the role of CAR T-cell therapy in relapsed/refractory multiple myeloma.
Latest:
Dr. Anwer on the Efficacy of CAR T-Cell Therapy in Multiple MyelomaFaiz Anwer, MD, discusses the efficacy of CAR T-cell therapy in multiple myeloma.
Latest:
Tumor-Treating Field Therapy Looks Beyond Brain CancerTumor-treating field therapy, which uses low-intensity electrical fields to disrupt cancer cell division and promote cell death, has gained a frontline approval in glioblastoma. Several pivotal clinical trials have been launched to determine whether the technology can help patients with other solid tumors.
